Cytosolic phospholipase A2α regulates cell growth in RET/PTC-transformed thyroid cells

Cancer Research

Volumn 67, Issue 24, 2007, Pages 11769-11778

  Mariggiò, Stefania ^a   Filippi, Beatrice Maria ^a,d   Iurisci, Cristiano ^a   Dragani, Luana Katia ^b   De Falco, Valentina ^c   Santoro, Massimo ^c   Corda, Daniela ^a  

^a Consorzio Mario Negri Sud ^*  (Italy)

^b Environmental Health Center   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ISOENZYME; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2ALPHA; THYROTROPIN; UNCLASSIFIED DRUG; PHOSPHOLIPASE A2 GROUP IV; THYMIDINE;

ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CYTOSOL; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE FUNCTION; ONCOGENE; ONCOGENE PTC; ONCOGENE RET; PRIORITY JOURNAL; PROTEIN FUNCTION; THYROID CELL; THYROID PAPILLARY CARCINOMA; ANIMAL; CELL DIVISION; CELL LINE; CELL TRANSFORMATION; CYTOLOGY; ENZYMOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY; RAT; THYROID GLAND;

ANIMALS; CELL DIVISION; CELL LINE; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, NEOPLASTIC; CYTOSOL; GROUP IV PHOSPHOLIPASES A2; RATS; THYMIDINE; THYROID GLAND;

EID: 37549065567     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-1997     Document Type: Article

References (49)

1. 2. Prostaglandins Leukot Essent Fatty Acids 2003;69:87-97.
2. Leslie CC. Regulation of arachidonic acid availability for eicosanoid production. Biochem Cell Biol 2004;82:1-17.
3. 2 enzymes. Prostaglandins Other Lipid Mediat 2002;68-9:3-58.
4. 2. Biochim Biophys Acta 2000;1488:124-38.
5. 2 superfamily and its group numbering system. Biochim Biophys Acta 2006;1761:1246-59.
6. 2α-derived phosphoinositide metabolite. FASEB J 2006;20:2567-9.
7. Kimura T, Van Keymeulen A, Golstein J, et al. Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr Rev 2001;22:631-56.
8. 2 activity, glycerophosphoinositol production and phosphoinositide synthesis in thyroid cells. Cell Signal 1991;3:321-32.
9. Corda D, Iurisci C, Berrie CP. Biological activities and metabolism of the lysophosphoinositides and glycerophosphoinositols. Biochim Biophys Acta 2002;1582:52-69.
10. Alonso T, Morgan RO, Marvizon JC, Zarbl H, Santos E. Malignant transformation by ras and other oncogenes produces common alterations in inositol phospholipid signaling pathways. Proc Natl Acad Sci U S A 1988;85:4271-5.
11. Berrie CP, Iurisci C, Corda D. Membrane transport and in vitro metabolism of the Ras cascade messenger, glycerophosphoinositol 4-phosphate. Eur J Biochem 1999;266:413-9.
12. 2 mass evaluation in Ras-transformed cells. Eur J Cancer 2002;38:2463-75.
13. Melillo RM, Castellone MD, Guarino V, et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 2005;115:1068-81.
14. Santoro M, Melillo RM, Carlomagno F, Vecchio G, Fusco A. Minireview: RET: normal and abnormal functions. Endocrinology 2004;145:5448-51.
15. Santoro M, Carlomagno F, Melillo RM, Fusco A. Dysfunction of the RET receptor in human cancer. Cell Mol Life Sci 2004;61:2954-64.
16. Ichihara M, Murakumo Y, Takahashi M. RET and neuroendocrine tumors. Cancer Lett 2004;204:197-211.
17. Fagin JA. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J Endocrinol 2004;183:249-56.
18. 2α, pyrrophenone. Biochem J 2002;363:727-35.
19. Ryan AJ, Wedge SR. ZD6474 - a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br J Cancer 2005;92 Suppl 1:S6-13.
20. Fusco A, Berlingieri MT, Di Fiore PP, et al. One- and two-step transformations of rat thyroid epithelial cells by retroviral oncogenes. Mol Cell Biol 1987;7:3365-70.
21. Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T. Ligands for peroxisome proliferator-activated receptor γ inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab2001;86:21 70-7.
22. Ishizaka Y, Ushijima T, Sugimura T, Nagao M. cDNA cloning and characterization of ret activated in a human papillary thyroid carcinoma cell line. Biochem Biophys Res Commun 1990;168:402-8.
23. 2. J Biol Chem 2004;279:11320-6.
24. Falasca M, Silletta MG, Carvelli A, et al. Signalling pathways involved in the mitogenic action of lysophosphatidylinositol. Oncogene 1995;10:2113-24.
25. Berrie CP, Iurisci C, Piccolo E, Bagnati R, Corda D. Analysis of the phosphoinositides and their aqueous metabolites. Methods Enzymol 2007;434:187-232.
26. Dragani LK, Berrie CP, Corda D, Rotilio D. Analysis of glycerophosphoinositol by liquid chromatography-electrospray ionisation tandem mass spectrometry using a β-cyclodextrin-bonded column. J Chromatogr B 2004;802:283-9.
27. Brondello JM, Brunet A, Pouyssegur J, McKenzie FR. The dual specificity mitogen-activated protein kinase phosphatase-1 and -2 are induced by the p42/p44MAPK cascade. J Biol Chem 1997;272:1368-76.
28. Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002;62:7284-90.
29. Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003;63:1454-7.
30. 2 based on native peptide inhibition. J Biol Chem 2001;276:33156-64.
31. 2 by bromoenol lactone and trifluoromethyl ketones. J Biol Chem 1995;270:445-50.
32. Hayashi H, Ichihara M, Iwashita T, et al. Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor. Oncogene 2000;19:4469-75.
33. Castellone MD, Cirafici AM, De Vita G, et al. Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes. Oncogene 2003;22:246-55.
34. 2 by p42 mitogen-activated protein kinase results in an increase in specific activity. Eur J Biochem 1996;238:690-7.
35. Kumar S, Jiang MS, Adams JL, Lee JC. Pyridinylimidazole compound SB 203580 inhibits the activity but not the activation of p38 mitogen-activated protein kinase. Biochem Biophys Res Commun 1999;263:825-31.
36. Basolo F, Giannini R, Monaco C, et al. Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. Am J Pathol 2002;160:247-54.
37. Vitagliano D, Portella G, Troncone G, et al. Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas. Oncogene 2006;25:5467-74.
38. Pierotti MA. Chromosomal rearrangements in thyroid carcinomas: a recombination or death dilemma. Cancer Lett 2001;166:1-7.
39. Alberti L, Carniti C, Miranda C, Roccato E, Pierotti MA. RET and NTRK1 proto-oncogenes in human diseases. J Cell Physiol 2003;195:168-86.
40. Fusco A, Viglietto G, Santoro M. A new mechanism of BRAF activation in human thyroid papillary carcinomas. J Clin Invest 2005;115:20-3.
41. 2α and arachidonic acid in cancer. Biochim Biophys Acta 2006;1761:1335-43.
42. Min-induced tumorigenesis. Proc Natl Acad Sci U S A 2001;98:3935-9.
43. 2 gene. J Biol Chem 2000;275:34013-6.
44. 2 and COX-2 expression during mouse colon tumorigenesis. Carcinogenesis 2003;24:307-15.
45. 2α through fine regulation of ERK phosphorylation. Cell Signal 2006;18:2200-8.
46. De Falco V, Castellone MD, De Vita G, et al. RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase. Cancer Res 2007;67:381-90.
47. Segouffin-Cariou C, Billaud M. Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. J Biol Chem 2000;275:3568-76.
48. Melillo RM, Santoro M, Ong SH, et al. Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade. Mol Cell Biol 2001;21:4177-87.
49. Borrello MG, Alberti L, Arighi E, et al. The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cγ. Mol Cell Biol 1996;16:2151-63.